Expertise in
8
conditions

David Azria

CRLC Val D'Aurelle
Montpellier, FR 
Expertise in
8
conditions
CRLC Val D'Aurelle
Montpellier, FR 

Overview

David Azria practices practicing medicine in Montpellier, France.

Mr. Azria is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Neuroendocrine Carcinoma of the Cervix, Breast Cancer, Mastectomy, and Prostatectomy.

He is actively involved in clinical research, co-authoring 274 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

CRLC Val d'Aurelle
Montpellier, 34000, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors
Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Radiation
Study Phase: Not Applicable
Multicenter Prospective Evaluation of a Predictive Test of Late Toxicities After Radiotherapy by the Rate of Radiation Induced CD8 T-Lymphocyte Apoptosis: Application to Breast and Prostate Cancers.
Multicenter Prospective Evaluation of a Predictive Test of Late Toxicities After Radiotherapy by the Rate of Radiation Induced CD8 T-Lymphocyte Apoptosis: Application to Breast and Prostate Cancers.
Enrollment Status: Completed
Publish Date: February 05, 2026
A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer
A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer
Enrollment Status: Terminated
Publish Date: October 10, 2025
Intervention Type: Other
Study Drugs: Cisplatin, Gemcitabine
Study Phase: Not Applicable
An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients
An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Radiation, Drug
Study Drugs: Apalutamide, Luteinising Hormone Releasing Hormone agonist
Study Phase: Phase 3
Phase I/II Multi-center Study Evaluating the Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence After External Radiation Therapy
Phase I/II Multi-center Study Evaluating the Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence After External Radiation Therapy
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Genetic
Study Phase: Not Applicable
Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis
Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis
Enrollment Status: Completed
Publish Date: June 13, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

274 Total Publications

Implementation of an AI-Driven Workflow for Daily Dose Reconstruction in Prostate Cancer Radiotherapy.
Implementation of an AI-Driven Workflow for Daily Dose Reconstruction in Prostate Cancer Radiotherapy.
Journal: Cancers
Published: March 31, 2026

Frequently Asked Questions about David Azria

Is David Azria a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. David Azria is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does David Azria participate in research or clinical trials?

Yes. David Azria has published 274 articles and abstracts on conditions like Prostate Cancer. You can view a list of David Azria's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Azria's expertise for a condition
ConditionClose
    View All 28 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile